NCT00436618View on ClinicalTrials.gov

Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

277

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

December 31, 2010

Study Completion Date

October 9, 2019

Conditions
LeukemiaLymphomaLymphoproliferative Disorder
Interventions
DRUG

Everolimus

Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.

Trial Locations (3)

32224

Mayo Clinic - Jacksonville, Jacksonville

55905

Mayo Clinic Cancer Center, Rochester

85259-5499

Mayo Clinic Scottsdale, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER